



**31 October 2023**

## **ASX Announcement Island Annual General Meeting - online link for shareholders**

MELBOURNE Australia, 31 October 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to invite those shareholders unable to join the Company's 2023 Annual General Meeting (AGM) in person, to watch the meeting online.

### **AGM - physical meeting location**

In line with the Notice of Meeting (ASX announcement: 13 October 2023), the physical meeting will be held on 16 November 2023 at 11:30am at:

K&L Gates  
31/1 O'Connell St  
Sydney NSW 2000

### **Video streaming link**

Shareholders unable to attend the meeting in person are invited to view the meeting proceedings via the below link. Please note those who view online will not be able to vote online via the below link and are instead encouraged to complete their voting via the means noted in the Notice of Meeting (ASX announcement: 13 October 2023).

Shareholders wishing to view the AGM virtually are invited to do so by registering attendance and using the following link:

[https://us02web.zoom.us/webinar/register/WN\\_HPn5yRI7RWWZfyDkYUn6wg](https://us02web.zoom.us/webinar/register/WN_HPn5yRI7RWWZfyDkYUn6wg)

The Island team looks forward to welcoming all those shareholders able to attend on the day.

--ends--

### **Approved for release to the ASX by:**

Dr Paul MacLeman  
Executive Chairman  
Island Pharmaceuticals Ltd  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

Investors and media, for further information, please contact:

Jane Lowe  
IR Department  
Mobile: +61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)



## About Island Pharmaceuticals

---

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.